Pancreatic Cancer Incidence Rising: New Research Offers Hope for Early Detection and Treatment
Table of Contents
A concerning trend is emerging in Europe: pancreatic cancer is now the fourth leading cause of cancer-related deaths, and projections indicate it could become the second by 2030 without significant advancements in treatment.
Pancreatic cancer, a disease with a notoriously grim prognosis, affected approximately 16,000 peopel in France in 2023. The incidence rate continues to climb, increasing by 1.6% annually for men and 2.1% for women between 2010 and 2023, primarily impacting individuals over the age of 50. Currently, the five-year survival rate stands at a sobering 11%.
The Challenge of Late Diagnosis
One of the most significant hurdles in combating pancreatic cancer is its tendency to be diagnosed late. Often, symptoms don’t appear until the tumor has spread beyond the pancreas, making surgical intervention – currently the only possibly curative treatment – unachievable in 80 to 90% of cases.As one expert noted, “The treatment then relies on heavy chemotherapy, which is too often insufficient.” The lack of specific, easily identifiable early symptoms further complicates timely diagnosis.
A Call for Innovation: The PANCREAS Project
Recognizing the urgent need for new strategies,the ARC Cancer Foundation launched the PANCREAS call for projects in 2022. The initiative aims to support groundbreaking research focused on early diagnosis, novel therapeutic approaches for patients ineligible for surgery, and identifying vulnerable points within the tumor microenvironment to overcome treatment resistance.
The foundation is currently supporting three promising projects:
Blocking IL-1 to Enhance Treatment Response
Researchers led by Professor François Ghiringhelli at the Center Georges François leclerc in Dijon are investigating the role of interleukin-1 (IL-1), a protein produced by the immune system. Their hypothesis suggests that IL-1 may allow tumor cells to shield themselves from treatment. The team is exploring whether blocking the IL-1 pathway could restore sensitivity to existing therapies.
Gene Therapy to Unleash the Immune System
Professor Sandrine Dabernat from the Bordeaux Oncology Research Institute is pioneering a gene therapy approach designed to weaken the tumor and create an environment more receptive to immune cell attack. “We offer an innovative gene therapy to create gaps in the tumor microenvironment and attract anti-tumor immune cells, making patients eligible for cellular immunotherapy,” she explained. This involves utilizing modified viruses to target pancreatic cancer cells, rendering them vulnerable to the body’s natural defenses.
Liquid Biopsies for Early Detection
Also led by Professor Dabernat, this project focuses on detecting pancreatic cancer at its earliest stages using a liquid biopsy – a simple blood test. This innovative approach analyzes the unique biological characteristics of immune cells associated with precancerous pancreatic lesions, potentially enabling earlier diagnosis and expanding surgical options for patients.
Recognizing the Warning signs
Early detection is crucial, and vigilance is key. The Léon-Bérard cancer centre in Lyon has identified several symptoms that shoudl prompt medical consultation:
- jaundice
- Abdominal pain
- Pain in the middle of the back
- New-onset diabetes
- Thrombosis
- Changes in intestinal transit
- Unexplained weight loss
- Nausea
- Depressed mood
For more extensive information about pancreatic cancer, resources are available on the website of the National Cancer Institute (Inca).
The rising incidence of pancreatic cancer demands immediate and sustained investment in research and early detection strategies. The projects supported by the ARC Cancer Foundation represent a critical step toward improving outcomes for patients facing this devastating disease.
